Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates

Vaccine

Volumn 29, Issue 35, 2011, Pages 6049-6058

  Marsh, Jane W ^a   Shutt, Kathleen A ^a   Pajon, Rolando ^b   Tulenko, Mary M ^a   Liu, Stephen ^a   Hollick, Rosemary A ^c   Kiehlbauch, Julia A ^d   Clark, Thomas A ^e   Stephens, David S ^f,g   Arnold, Kathryn E ^h   Myers, Robert A ^d   Mayer, Leonard W ^e   Harrison, Lee H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f EMORY UNIVERSITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h Georgia Division of Public Health and Emerging Infections Program   (United States)

Author keywords

FHbp; Genetic lineage; Meningococcal vaccine; Recombination

Indexed keywords

BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN; FACTOR H BINDING PROTEIN VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BACTERIUM ISOLATE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC RECOMBINATION; GENOTYPE; GEORGIA (REPUBLIC); HOMOPLASY; HUMAN; MAJOR CLINICAL STUDY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; UNITED STATES;

ADOLESCENT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CARRIER STATE; GENETIC VARIATION; GEORGIA; HUMANS; MARYLAND; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RECOMBINATION, GENETIC; SEROTYPING;

EID: 79960845205     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.025     Document Type: Article

References (44)

1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(June (Suppl. 2)):B51-B63.
2. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138(June (12)):4402-4407.
3. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(August (8346)):355-357.
4. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(March (Suppl. 2)):S54-S65.
5. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(April (4)):2088-2100.
6. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(March (6)):789-799.
7. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176(June (12)):7566-7575.
8. Beernink P.T., Granoff D.M. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009, 155(September (Pt 9)):2873-2883.
9. Russell J.E., Jolley K.A., Feavers I.M., Maiden M.C., Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10(April (4)):674-678.
10. Trotter C.L., Maiden M.C. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009, 8(July (7)):851-861.
11. Bjune G. " Herd immunity" and the meningococcal vaccine trial in Norway. Lancet 1992, 340(August (8814)):315.
12. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile, Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13(June (9)):821-829.
13. Holmes J.D., Martin D., Ramsay C., Ypma E., Oster P. Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. Epidemiol Infect 2008, 136(June (6)):790-799.
14. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998, 177(March (3)):683-691.
15. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(July (29)):10834-10839.
16. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(August (3)):379-389.
17. Seib K.L., Oriente F., Adu-Bobie J., Montanari P., Ferlicca F., Giuliani M.M., et al. Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine 2010, 28(March (12)):2416-2427.
18. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29(February (7)):1413-1420.
19. Dolan-Livengood J.M., Miller Y.K., Martin L.E., Urwin R., Stephens D.S. Genetic basis for nongroupable Neisseria meningitidis. J Infect Dis 2003, 187(May (10)):1616-1628.
20. Kellerman S.E., McCombs K., Ray M., Baughman W., Reeves M.W., Popovic T., et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002, 186(July (1)):40-48.
21. Clark T., Stern E., Pondo T., Arnold K., Harrison L., Vello M., et al. The effect of quadrivalent (A, C, Y,W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. 16th International pathogenic neissera conference 2008.
22. Mothershed E.A., Sacchi C.T., Whitney A.M., Barnett G.A., Ajello G.W., Schmink S., et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004, 42(January (1)):320-328.
23. Schuchat A., Hilger T., Zell E., Farley M.M., Reingold A., Harrison L., et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001, 7(January-February (1)):92-99.
24. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., Macneil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, (May).
25. Harrison L.H., Jolley K.A., Shutt K.A., Marsh J.W., O'Leary M., Sanza L.T., et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006, 193(May (9)):1266-1274.
26. Harrison L.H., Shutt K.A., Schmink S.E., Marsh J.W., Harcourt B.H., Wang X., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010, 201(April (8)):1208-1224.
27. Katz L.S., Bolen C.R., Harcourt B.H., Schmink S., Wang X., Kislyuk A., et al. Meningococcus genome informatics platform: a system for analyzing multilocus sequence typing data. Nucleic Acids Res 2009, 37(July (Web Server issue)):W606-W611.
28. Brehony C., Wilson D.J., Maiden M.C. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009, 155(December (Pt 12)):4155-4169.
29. Goodman L.A., Kruskal W.H. Measures of association for cross classifications. J Am Stat Assoc 1954, 49:732-764.
30. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(August (8)):1596-1599.
31. Wilson D.J., McVean G. Estimating diversifying selection and functional constraint in the presence of recombination. Genetics 2006, 172(March (3)):1411-1425.
32. Huson D.H., Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006, 23(February (2)):254-267.
33. Kosakovsky Pond S.L., Posada D., Gravenor M.B., Woelk C.H., Frost S.D. Automated phylogenetic detection of recombination using a genetic algorithm. Mol Biol Evol 2006, 23(October (10)):1891-1901.
34. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009, 47(November (11)):3577-3585.
35. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27(May (21)):2794-2803.
36. Mothibeli K.M., du Plessis M., von Gottberg A., Murphy E., Hoiseth S.K., Zlotnick G., et al. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 2011, 29(March (11)):2187-2192.
37. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107(November (45)):19490-19495.
38. Dull P.M., Pizza M., Toneatto D., DeTora L., Ypma E., Kleinschmidt A., et al. Early clinical development of a novel, multicomponent meningococcal serogroup B vaccine (4CMenB). International Pathogenic Neisseria Conference 2010.
39. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(November (10)):1127-1137.
40. Richmond P., Marshall H., Sheldon E., Jiang Q., Anderson A., Jansen K.U., et al. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent submects: overview of 3 clinical trials. International pathogenic neisseria conference 2010.
41. Brunelli B., Del Tordello E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011, 29(January (5)):1072-1081.
42. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(August (37)):6086-6093.
43. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28(February (9)):2122-2129.
44. Jolley K.A. Internet-based sequence-typing databases for bacterial molecular epidemiology. Methods Mol Biol 2009, 551:305-312.